Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease

Al-mansouri, Asmaa; Hamad, Abdullah; Al-Ali, Fadwa; Ibrahim, Mohamed Izham Mohamed; Kheir, Nadir; Al-Ziftawi, Nour Hisham; Ibrahim, Rania; Albakri, Muna; Awaisu, Ahmed

doi:10.1016/j.jsps.2023.03.008

Cited by 5 publications

(15 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Six were cross-sectional studies [ 14–16 , 19 , 21 , 22 ], one was a prospective cohort study [ 17 ], two were retrospective cohort studies [ 20 , 23 ], and one was an intervention cohort study [ 18 ]. One study was published in 2014 [ 21 ], one in 2017 [ 22 ], two in 2018 [ 14 , 15 ], one in 2019 [ 17 ], four in 2021 [ 18–20 , 23 ], and one most recently in 2023 [ 16 ]. One was from the Middle East [ 16 ], four from Asia [ 14 , 15 , 18 , 22 ], three from Europe [ 17 , 21 , 23 ], one from North America [ 20 ], and one from Australia [ 19 ].…”

Section: Resultsmentioning

confidence: 99%

“…One study was published in 2014 [ 21 ], one in 2017 [ 22 ], two in 2018 [ 14 , 15 ], one in 2019 [ 17 ], four in 2021 [ 18–20 , 23 ], and one most recently in 2023 [ 16 ]. One was from the Middle East [ 16 ], four from Asia [ 14 , 15 , 18 , 22 ], three from Europe [ 17 , 21 , 23 ], one from North America [ 20 ], and one from Australia [ 19 ]. The smallest study included 150 patients [ 18 ], and the largest study included 27,573 patients [ 23 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Medication burden in patients with dialysis-dependent CKD: a systematic review

Liu,

Chen,

Liu

et al. 2024

Renal Failure

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Medication burden in patients with dialysis-dependent CKD: a systematic review

Liu,

Chen,

Liu

et al. 2024

Renal Failure

View full text Add to dashboard Cite

“…This may indicate a level of trust in the healthcare system and emphasize the importance of patient education. The role of healthcare workers in educating older people has been reported in the literature [ 7 , 9 ]. As the population of older people continues to increase in LMICs, there is a need to increase and train community pharmacists to reach out and educate older people on the usefulness and side effects of polypharmacy [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…The WHO has acknowledged that polypharmacy prevalence is set to escalate with an increase in chronic disease [ 6 ]. Advanced chrpnic conditions such as chronic kidney disease is associated with polypharmacy [ 7 ]. In the US, the older the person the worse the degree of polypharmacy [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Knowledge, attitudes and beliefs toward polypharmacy among older people attending Family Medicine Clinic, Nairobi, Kenya

Kamau,

Nyanja,

Lusambili

et al. 2024

BMC Geriatr

View full text Add to dashboard Cite

Background Life expectancy has increased over the last century among older people, particularly those aged over 60 years. Aging is associated with increased disability, multiple chronic conditions, and increased use of health services managed with polypharmacy. There are few studies on polypharmacy and aging in sub-Saharan Africa, and it is unclear what older people know and their attitudes toward polypharmacy. This paper presents findings from a study that aimed to understand older people’s knowledge, attitudes and beliefs about polypharmacy. Methods A qualitative study using in-depth interviews of 15 patients aged 60 years and older who were taking more than five medications per day. The study was conducted at the Family Medicine Clinic (FMC), Aga Khan University Hospital, Nairobi. Data were analyzed using NVivo 12 software. Result Majority of participants had a good understanding of their underlying health conditions, but they did not know the specific names of the medications they were taking. Participants had diverse attitudes toward polypharmacy, with both positive and negative perceptions. Although adverse side effects were reported, participants remained positive because they believed these medicines were beneficial. Religion, faith and living healthy lifestyles were perceived to contribute to their positive attitude toward polypharmacy. Stigma and the cost of medication were reported as barriers. Conclusion This study provides valuable insights into the complexities of polypharmacy in older people. It highlights the importance of patient education, fostering strong patient-provider relationships, de-stigmatization, and improving medication affordability and accessibility. Further research could explore the polypharmacy of older people attending public institutions in rural Kenya.

show abstract

“…Etelcalcetide was found to be helpful in general to the patient’s overall personal perception of their compliance to their treatment regimens. Polypharmacy and pill-burden is a known issue that hinders compliance to medication and leads to poor clinical outcomes as well as poor quality of life [ 16 ]. Our study may demonstrate an overall strategy to use drug alternatives which are available in intravenous forms for chronic hemodialysis patients, to help reduce polypharmacy and pill burden.…”

Section: Discussionmentioning

confidence: 99%

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore

Khan,

Qu,

Hua

et al. 2023

Cureus

View full text Add to dashboard Cite

Introduction Chronic kidney disease-related mineral and bone disorder (CKD-MBD), characterized by abnormalities in calcium, phosphate, and parathyroid hormone metabolism, with impaired bone turnover and extravascular calcification is a known complication of advanced chronic kidney disease (CKD). Secondary hyperparathyroidism (SHPT) develops early in the disease and its prevalence gradually increases with the disease progression, becoming almost universal in patients with end-stage renal disease (ESRD). The treatment for SHPT includes synthetic vitamin D analogs, calcitriol or calcimimetics. Recently, intravenous etelcalcetide was introduced as a second-generation calcimimetic. This article provides the real-world experience of using etelcalcetide in multiethnic Asian patients receiving hemodialysis at community-based hemodialysis centers in Singapore. Methods This study was real-world evidence, generated by a retrospective clinical audit of routine clinical care of hemodialysis patients in community-based centers in Singapore who received etelcalcetide for treating SHPT. The information on the starting and maximum dose of etelcalcetide, duration of treatment on hemodialysis, parathyroid hormone (PTH) levels, dialysate calcium, concomitant medications, and reasons for discontinuation were collected from the medical records. PTH levels were collected at four-, eight-, and twelve-month intervals. Results A total of 148 patients received etelcalcetide during the study period. Ten patients died and twenty discontinued their treatment, with 118 patients remaining on treatment. Demographically, the patients included Chinese, Malay, Indians, and those belonging to other racial groups. The starting dose of etelcalcetide ranged from 2.5 mg once per week to 7.5 mg three times a week. There was a 16.8% reduction (p=<0.001) in intact-PTH after four months of therapy. Target intact-PTH level of less than 60 pmol/L, was reported as 1.4% at baseline, with 22.3% at four months (p<0.001) and 25.9% at eight months (p=0.028). Calcium and phosphate levels were also tracked as part of the safety and efficacy measures of using etelcalcetide. No symptomatic hypocalcemia was noted and phosphate levels were noted to decline significantly. Overall, the calcium-phosphate product reduced at four months (13.2%, p=<0.001) and eight months (12.7%, p<0.05). An analysis of concomitant medication usage, dialysate calcium utilized, and the side effects of etelcalcetide were also recorded. Finally, a brief descriptive analysis of the patient's subjective feedback regarding etelcalcetide was also reported, especially regarding the reduction in pill burden and overall compliance to medications. Conclusion Etelcalcetide is safe and effective for treating SHPT in multi-ethnic Asian hemodialysis patients and can be considered an alternative to oral cinacalcet. Our study showed no side effects, which was one of the key reasons for non-compliance to traditional calcimimetics...

show abstract

Pill-burden and its association with treatment burden among patients with advanced stages of chronic kidney disease

Cited by 5 publications

References 34 publications

Medication burden in patients with dialysis-dependent CKD: a systematic review

Medication burden in patients with dialysis-dependent CKD: a systematic review

Knowledge, attitudes and beliefs toward polypharmacy among older people attending Family Medicine Clinic, Nairobi, Kenya

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore

Contact Info

Product

Resources

About